Navigation Links
Transcept Pharmaceuticals to Present at Lazard Capital Markets Healthcare Conference on November 17
Date:11/10/2009

RICHMOND, Calif., Nov. 10 /PRNewswire-FirstCall/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT) today announced that it will present at the Lazard Capital Markets 6th Annual Healthcare Conference on Tuesday, November 17, at 2:10 p.m. Eastern Standard Time. A live audio webcast and replay of the presentation will be available on the Transcept investor webpage at www.transcept.com.

About Transcept

Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in neuroscience. The most advanced Transcept product candidate is Intermezzo® (zolpidem tartrate sublingual tablet), for which a New Drug Application (NDA) was submitted to the U.S. Food and Drug Administration (FDA) in September 2008 seeking approval as a prescription sleep aid for use in the middle of the night at the time a patient awakens and has difficulty returning to sleep. In October 2009, Transcept received a Complete Response Letter from the FDA on the Intermezzo® NDA and is working to respond to issues raised in the letter. Transcept and Purdue Pharmaceutical Products, L.P. have entered into a collaboration agreement for the development and commercialization of Intermezzo® in the United States. For further information, please visit the company's website at: www.transcept.com.

    Contact:

    Transcept Pharmaceuticals, Inc.
    Greg Mann
    Director, Corporate Communications
    (510) 215-3567
    gmann@transcept.com

SOURCE Transcept Pharmaceuticals, Inc.


'/>"/>
SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Transcept Pharmaceuticals to Report Third Quarter 2009 Results and Host Conference Call on November 12
2. Transcept Pharmaceuticals Receives Complete Response Letter from FDA on Intermezzo(R) New Drug Application
3. Transcept Pharmaceuticals to Report First Quarter 2009 Results
4. Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings
5. Transcept Pharmaceuticals Announces Intent to Submit New Drug Application for Intermezzo(R) in Third Quarter 2008
6. Vion Pharmaceuticals Reports 2009 Third Quarter and Nine-Month Results
7. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2009 Financial Results
8. Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments
9. ISTA Pharmaceuticals Highlights Bepreve(TM) Clinical Data at the 2009 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI)
10. Bend Research and Vertex Pharmaceuticals Enter New Scientific Collaboration
11. DUSA Pharmaceuticals to Present at the Merriman Curhan Ford Investor Summit 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2017)... 2017  The global market for liquid biopsy diagnostic ... million in 2016.  Although in early stages, the global ... particular as a result of the gradual shift towards ... introduction of a significant number of new liquid biopsy ... tumor biomarkers to guide treatment decisions. ...
(Date:7/10/2017)... , July 10, 2017 The Institute for ... methods, is the recipient of a VITROCELL® inhalation exposure ... International Science Consortium. The device, which is designed to ... expose human lung cells to airborne test materials in ... use the VITROCELL® system for testing combustible tobacco products, ...
(Date:7/5/2017)... , July 5, 2017 Wolfmet 3D  printed ... as physics and manufacturing combine to progress molecular radiotherapy imaging. ... SPECT systems are unable to accurately quantify the radiation absorbed ... information regarding the success of this radiotherapy treatment has been ... ...
Breaking Medicine Technology:
(Date:7/24/2017)... Cambridge, MA (PRWEB) , ... July 24, 2017 , ... ... for an invigorating and educational conference, InstructureCon. Each annual event is coupled with a ... next level with a James Bond theme, Mission: InstructureCon 0017. , To extend ...
(Date:7/24/2017)... ... July 24, 2017 , ... Puregraft, the ... announces the issuance of United States Patent Number 9,695,398 (the '398 patent) and ... The '398 and '324 patents cover methods and systems for optimizing fat ...
(Date:7/24/2017)... (PRWEB) , ... July 24, 2017 , ... Paul Vitenas, ... the nation’s top level plastic surgeons, invited to attend Allergan’s recent meeting with their ... most valued companies in the world, Allergan is bringing a newly defined structure to ...
(Date:7/24/2017)... VA (PRWEB) , ... July 24, 2017 , ... ... Managers, **Presented by FDAnews and MSceppa Consulting **, Aug. 22-23, 2017 – Arlington, ... on Friday, July 28. , Increased FDA scrutiny and growing demands to track ...
(Date:7/24/2017)... ... ... “Nana Nana Boo Boo”: a delightful tale of a young girl who ... Boo” is the creation of published author Michael Rush, a Deputy Sheriff, former world ... Rush’s new book presents the importance of manners in a way easily understood by ...
Breaking Medicine News(10 mins):